Torrent Pharmaceuticals has allotted 4.19 crore shares to J.B. Chemicals shareholders, finalizing its amalgamation. This increases its equity capital and share count, marking a key step in the integration process.

Torrent Pharmaceuticals Completes Share Allotment Post-Amalgamation

Torrent Pharmaceuticals has allotted 4,19,22,416 equity shares to J. B. Chemicals & Pharmaceuticals Limited shareholders. The issued and paid-up share capital now stands at ₹190.18 crore, with a total of 38,03,67,856 shares.

Reader Takeaway: Equity base expands post-amalgamation; monitor combined performance going forward.

What just happened

Torrent Pharmaceuticals Limited has formally executed the allotment of 4,19,22,416 fully paid-up equity shares. This action follows the National Company Law Tribunal's (NCLT) sanction order on July 6, 2026, for the amalgamation scheme involving J. B. Chemicals & Pharmaceuticals Limited.

The share allotment was approved by the Securities Transfer and Stakeholders Relationship Committee as per the record date of July 17, 2026.

Why this matters

This allotment signifies the completion of the share transfer phase of the amalgamation. It directly impacts the company's equity structure by increasing its paid-up share capital and the total number of outstanding shares. The new shares rank equally with existing equity shares.

The backstory

The amalgamation scheme was sanctioned by the NCLT. The key terms included a share exchange ratio where J. B. Chemicals shareholders received 51 Torrent Pharmaceuticals shares for every 100 J. B. Chemicals shares held. The face value of Torrent Pharma shares is ₹5.

What changes now

The company's issued and paid-up capital has increased from ₹169.22 crore to ₹190.18 crore. The total number of shares has risen from 33,84,45,440 to 38,03,67,856. This marks the final implementation step of the NCLT-approved scheme.

Investor Takeaway

For investors, this means the equity base has expanded due to the issuance of new shares. The integration process is now largely complete from a share allotment perspective. Future performance will reflect the combined operations of both entities.

What to track next

Investors should now focus on the operational synergies and the combined business performance of the merged entity in upcoming quarterly financial reports.